Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

NCT01788046 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

515

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperparathyroidism, Secondary

Interventions

DRUG: Etelcalcetide
DRUG: Placebo

Sponsor

Amgen